WebVous êtes ici Accueil » A Randomized Non-Comparative Phase II Study of Anti-Programmed Cell Death-Ligand 1 Atezolizumab or Chemotherapy as Second-Line Therapy in Patients … Web朱燕 吴世凯. 1 小细胞肺癌（small cell lung cancer, SCLC）的免疫治疗进展和存在的问题. 肺癌是发病率和死亡率最高的实体肿瘤类型[1]，其中，SCLC约占肺癌总发病率的10%[1]，其特点为恶性度高、生长速度快、早期易发生转移，预后极差。

(PDF) MicroRNA-206 suppresses mesothelioma progression via …

WebPujol J-L, Greillier L, Audigier-Valette C, et al. A randomized non-comparative phase 2 study of anti-programmed cell death-ligand 1 atezolizumab or chemotherapy as second-line therapy in patients with small cell lung cancer: results from the IFCT-1603 Trial. J Thorac Oncol. 2024;S1556-0864(19):30025. 44. National Cancer Institute (NCI). WebA randomized non-comparative phase II study of anti-programmed cell death-ligand 1 atezolizumab or chemotherapy as second-line therapy in patients with small cell lung cancer: Results from the IFCT-1603 trial. J Thorac Oncol (2024) 14 (5):903–13. doi: 10.1016/j.jtho.2024.01.008 [Google Scholar] heroma sotenäs

Frontiers Immune Check Point Inhibitors and Immune-Related …

WebIn 2007, the FDA approved topotecan as a second-line treatment option for SCLC. The response rate to topotecan of patients who have relapsed is 20–25%, with a 1-year … WebIFCT-1603: National Competent Authority: France - ANSM: Clinical Trial Type: EEA CTA: Trial Status: Completed: Date on which this record was first entered in the EudraCT … Web23 feb. 2024 · Contraceptive methods acceptable to the IFCT, when used consistently and in accordance with both the product label and the instructions of the physician, are as … hero market taman tun dr ismail